Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab
Clinical trial NCT04869358 · COMPLETED
Trial details
- NCT number
- NCT04869358
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-27
- Primary completion
- 2022-05-10
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.